Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Koen M. A. Dreijerink, Ph.D., M.D.

TitleResearch Fellow in Medicine (EXT)
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressDana-Farber Cancer Institute
Dana 728
44 Binney St
Boston MA 02115

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Dreijerink KM, Goudet P, Burgess JR, Valk GD. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014 Aug 7; 371(6):583-4.
    View in: PubMed
  2. Dreijerink KM, Kampschreur LM, Lentjes EG, Lokhorst B, Zelissen PM. Atypical hypocortisolism. Endocr Pract. 2013 Sep-Oct; 19(5):e112-4.
    View in: PubMed
  3. Mannstadt M, Harris M, Bravenboer B, Chitturi S, Dreijerink KM, Lambright DG, Lim ET, Daly MJ, Gabriel S, Jüppner H. Germline mutations affecting Ga11 in hypoparathyroidism. N Engl J Med. 2013 Jun 27; 368(26):2532-4.
    View in: PubMed
  4. van Wijk JP, Dreijerink KM, Pieterman CR, Lips CJ, Zelissen PM, Valk GD. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol (Oxf). 2012 Jan; 76(1):67-71.
    View in: PubMed
  5. Lips CJ, Dreijerink KM, Höppener JW. Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics (Sao Paulo). 2012; 67 Suppl 1:49-56.
    View in: PubMed
  6. Pieterman CR, Vriens MR, Dreijerink KM, van der Luijt RB, Valk GD. Care for patients with multiple endocrine neoplasia type 1: the current evidence base. Fam Cancer. 2011 Mar; 10(1):157-71.
    View in: PubMed
  7. Dreijerink KM, Varier RA, van Nuland R, Broekhuizen R, Valk GD, van der Wal JE, Lips CJ, Kummer JA, Timmers HT. Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol Cell Endocrinol. 2009 Dec 10; 313(1-2):1-8.
    View in: PubMed
  8. Gracanin A, Dreijerink KM, van der Luijt RB, Lips CJ, Höppener JW. Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Cancer Res. 2009 Aug 15; 69(16):6371-4.
    View in: PubMed
  9. Dreijerink KM, Varier RA, van Beekum O, Jeninga EH, Höppener JW, Lips CJ, Kummer JA, Kalkhoven E, Timmers HT. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol. 2009 Sep; 29(18):5060-9.
    View in: PubMed
  10. Dreijerink KM, Lips CJ, Timmers HT. Multiple endocrine neoplasia type 1: a chromatin writer's block. J Intern Med. 2009 Jul; 266(1):53-9.
    View in: PubMed
  11. Dreijerink KM, Höppener JW, Timmers HM, Lips CJ. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab. 2006 Oct; 2(10):562-70.
    View in: PubMed
  12. Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 2006 May 1; 66(9):4929-35.
    View in: PubMed
  13. Dreijerink KM, van Beek AP, Lentjes EG, Post JG, van der Luijt RB, Canninga-van Dijk MR, Lips CJ. Acromegaly in a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease. Eur J Endocrinol. 2005 Dec; 153(6):741-6.
    View in: PubMed
  14. Dreijerink KM, Lips CJ. Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1). Hered Cancer Clin Pract. 2005; 3(1):1-6.
    View in: PubMed
  15. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM, Lerman MI. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002 Jun 15; 62(12):3498-502.
    View in: PubMed
  16. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7504-9.
    View in: PubMed
  17. Dreijerink KM, Roijers JF, van der Luijt RB, Höppener JW, Lips CJ. [Multiple endocrine neoplasia type 1: recent developments and guidelines for DNA diagnosis and periodic clinical monitoring]. Ned Tijdschr Geneeskd. 2000 Dec 16; 144(51):2445-9.
    View in: PubMed
  18. Dreijerink KM, Roijers JF, Jansen-Schillhorn van Veen JM, Neijt JP, van Vroonhoven TJ, Lips CJ. [Diverse expression of multiple endocrine neoplasia type 1]. Ned Tijdschr Geneeskd. 2000 Dec 16; 144(51):2437-42.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Dreijerink's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department